A randomized, open labeled, comparative study to assess the efficacy and safety of controller medications as add on to inhaled corticosteroid and long-acting β2 agonist in the treatment of moderate-to-severe persistent asthma

Journal of Postgraduate Medicine

Volumn 56, Issue 4, 2010, Pages 270-274

  Patel, Y A ^a   Patel, P ^a   Bavadia, H ^a   Dave, J ^a   Tripathi, C B ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

add on therapy; Asthma; doxophylline; inhaled corticosteroid; long acting beta2 agonist; montelukast sodium

Indexed keywords

BUDESONIDE; DOXOFYLLINE; FORMOTEROL; MONTELUKAST;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANOREXIA; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; MALE; MODERATE PERSISTENT ASTHMA; NAUSEA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SEVERE PERSISTENT ASTHMA; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

ACETATES; ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; QUINOLINES; THEOPHYLLINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77958017423     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.70937     Document Type: Article

References (29)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Bethesda: National Institutes of Health, 2003. NIH Publication No. 02-3659.
2. Lemanske RF Jr, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy J V, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001;285:2594-603.
3. 2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001;285:2583-93.
4. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels R, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL Study. Am J Respir Crit Care Med 2004;170:836-44.
5. Rabe K F, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114:40-7.
6. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2001;107:614.
7. Ringdal N, Eliraz A, Pruzinec R, Weber HH, Mulder PG, Akveld M, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003;97:234-41.
8. Kanniess F, Richter K, Bohme S, Jorres R A, Magnussen H. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J 2002;20:853-8.
9. The American Lung Association Asthma Clinical Research Centers. Clinical Trial of Low dose Theophylline and Montelukast in Patients with Poorly Controlled Asthma. Am J Respir Crit Care Med 2007;175:235-42.
10. Barnes PJ. Theophylline: New Perspectives for an Old Drug. Am J Respir Crit Care Med 2003;167:813-8.
11. Evans DJ, Taylor DA, Zetterstrom O, Chung K F, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337:1412-8.
12. Ukena D, Harnest U, Sakalaukas R, Magyar P, Vetter N, Steffen H, et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 1997;10:2754-60.
13. th ed. New Delhi: Jaypee Brothers medical Publishers; 2008. p. 221.
14. Juniper E, O'Byrne P, Guyatt G, Ferrie P, King D. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-7.
15. Juniper E F, Bousquet J, Abetz L, Bateman ED. The GOAL Committee. Identifying 'well controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 2006;100:616-21.
16. Vaquerizo MJ, Casan P, Castillo J, Perpina M, Sanchis J, Sobradillo V, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003;58:204-10.
17. Mascali JJ, Cvietusa P, Negri J, Borish L. Anti-inflammatory effects of theophylline: modulation of cytokine production. Ann Allergy Asthma Immunol 1996;77:34-8.
18. Tenor H, Hatzelmann A, Church MK, Schudt C, Shute JK. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 1996;118:1727-35.
19. Condino-Neto A, Vilela MM, Cambiucci EC, Ribeiro JD, Guglielmi AA, Magna LA, et al. Theophylline therapy inhibits neutrophil and mononuclear cell chemotaxis from chronic asthmatic children. Br J Clin Pharmacol 1991;32:557-61.
20. Umeda M, Ichiyama T, Hasegawa S, Kaneko M, Matsubara T, Furukawa S. Theophylline inhibits NF-kappaB activation in human peripheral blood mononuclear cells. Int Arch Allergy Immunol 2002;128:130-5.
21. Kidney J, Dominguez M, Taylor PM, Rose M, Chung K F, Barnes PJ. Immunomodulation by theophylline in asthma. Am J Respir Crit Care Med 1995;151:1907-14.
22. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Anti-inflammatory effects of low dose oral theophylline in atopic asthma. Lancet 1994;343:1006-8.
23. Virchow JC, Mehta A, Ljungblad Li, Mitfessel H. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: The MONtelukast In Chronic Asthma (MONICA) study. Respir Med 2010;104:644-51.
24. Keith PK, Koch C, Djandji M, Bouchard J, Psaradellis E, Sampalis JS, et al. Montelukast as add-on therapy with inhaled corticosteroids or inhaled corticosteroids and long-acting β-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (The RADAR Trial). Can Respir J 2009;16:17-24.
25. Shah AR, Sharples LD, Solanki RN, Shah K V. Double-Blind, Randomised, Controlled Trial Assessing Controller Medications in Asthma. Respiration 2006;73:449-56.
26. 2-Agonists in Achieving Asthma Control. Chest 2008;134;1192-9.
27. Virchow JC Jr, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000;162:578-85.
28. 2-agonists: addition of montelukast in an open-label pilot study. Curr Med Res Opin 2005;21:863-9.
29. Korn D, Van den B P, Potvin E, Dramaix M, Herbots E, Peche R. Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study. Curr Med Res Opin 2009;25:489-97.